Abstract:l-3,4-dihydroxyphenylalanine (l-DOPA) is an effective treatment for Parkinson's disease (PD); however, long-term treatment induces l-DOPA-induced dyskinesia (LID). To elucidate its pathophysiology, we developed a mouse model of LID by daily administration of l-DOPA to PD male ICR mice treated with 6-hydroxydopamine (6-OHDA), and recorded the spontaneous and cortically evoked neuronal activity in the external segment of the globus pallidus (GPe) and substantia nigra pars reticulata (SNr), the connecting and output nuclei of the basal ganglia, respectively, in awake conditions. Spontaneous firing rates of GPe neurons were decreased in the dyskinesia-off state (≥24 h after l-DOPA injection) and increased in the dyskinesia-on state (20–100 min after l-DOPA injection while showing dyskinesia), while those of SNr neurons showed no significant changes. GPe and SNr neurons showed bursting activity and low-frequency oscillation in the PD, dyskinesia-off, and dyskinesia-on states. In the GPe, cortically evoked late excitation was increased in the PD and dyskinesia-off states but decreased in the dyskinesia-on state. In the SNr, cortically evoked inhibition was largely suppressed, and monophasic excitation became dominant in the PD state. Chronic l-DOPA treatment partially recovered inhibition and suppressed late excitation in the dyskinesia-off state. In the dyskinesia-on state, inhibition was further enhanced, and late excitation was largely suppressed. Cortically evoked inhibition and late excitation in the SNr are mediated by the cortico-striato-SNr direct and cortico-striato-GPe-subthalamo-SNr indirect pathways, respectively. Thus, in the dyskinesia-on state, signals through the direct pathway that release movements are enhanced, while signals through the indirect pathway that stop movements are suppressed, underlying LID. SIGNIFICANCE STATEMENT Parkinson's disease (PD) is caused by progressive loss of midbrain dopaminergic neurons, characterized by tremor, rigidity, and akinesia, and estimated to affect around six million people world-wide. Dopamine replacement therapy is the gold standard for PD treatment; however, control of symptoms using l-3,4-dihydroxyphenylalanine (l-DOPA) becomes difficult over time because of abnormal involuntary movements (AIMs) known as l-DOPA-induced dyskinesia (LID), one of the major issues for advanced PD. Our electrophysiological data suggest that dynamic changes in the basal ganglia circuitry underlie LID; signals through the direct pathway that release movements are enhanced, while signals through the indirect pathway that stop movements are suppressed. These results will provide the rationale for the development of more effective treatments for LID.

Dopamine D3 Receptor Modulates L-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling

The Dynamics of Dopamine D 2 Receptor-Expressing Striatal Neurons and the Downstream Circuit Underlying L-Dopa-Induced Dyskinesia in Rats

D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse

Inhibition of Striatal Dopamine D5 Receptor Attenuates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.

Differential activation states of direct pathway striatal output neurons during L-DOPA-induced dyskinesia development.

Targeting the D1-N-methyl-D-aspartate Receptor Complex Reduces L-dopa-induced Dyskinesia in 6-Hydroxydopamine-lesioned Parkinson’s Rats

Inhibition of striatal dopamine D5 receptor attenuates levodopa-induced dyskinesia in a rat model of Parkinson’s disease

Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of L-DOPA-Induced Dyskinesia

Striatal D1 Dopamine Neuronal Population Dynamics in a Rat Model of Levodopa-Induced Dyskinesia

L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia

5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice

Cortico-striatal Gamma Oscillations Are Modulated by Dopamine D3 Receptors in Dyskinetic Rats

Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease

Inhibition of Glycogen Synthase Kinase-3β (Gsk-3Β) As Potent Therapeutic Strategy to Ameliorates L-dopa-induced Dyskinesia in 6-OHDA Parkinsonian Rats

Functional Changes of D1 Dopamine Receptor in Striatal Neurons of Rats with Levodopa-induced Dyskinesias

Dopamine D2L Receptor Deficiency Alters Neuronal Excitability and Spine Formation in Mouse Striatum

The Abnormal Activation of D1R/Shp-2 Complex Involved in Levodopa-Induced Dyskinesia in 6-Hydroxydopamine-lesioned Parkinson's Rats.

Rewarding properties of L-Dopa in experimental parkinsonism are mediated by sensitized dopamine D1 receptors in the dorsal striatum

Activation of mGlu 2/3 receptors in the striatum alleviates L-DOPA-induced dyskinesia and inhibits abnormal postsynaptic molecular expression

Dopamine Receptor 3 Might Be an Essential Molecule in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity.

Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine.